ClinicalTrials.gg
RecruitingNCT07145151MASHUpdated Nov 3, 2026

A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

A Phase 2 interventional study of UBT251 and Placebo in Metabolic Dysfunction-associated Steatohepatitis (MASH), sponsored by The United Bio-Technology (Hengqin) Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by The United Bio-Technology (Hengqin) Co., Ltd. (part of The United Laboratories International Holdings Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 63 studies in Fatty Liver with a site in China — 30 open to participants now, 34 under way, 2 of them phase 3. Fatty Liver · China.

Planned enrollment
11th of 37
156 · median 90
Started
2025
with 11 others
Phase 2
8 of 63
5 open now
Primary completion
2027-06
later than 19 of 33 live
Registered
47th of 63
by date

Among the 63 studies in Fatty Liver with a site in China, this one is the 11th largest by planned enrollment of the 37 interventional ones that give a count, is one of 12 that started in 2025, is one of 8 in phase 2, reaches primary completion later than 19 of the 33 other live ones, and was the 47th registered.

Fatty Liver

663 studies on the registry are indexed under Fatty Liver; 185 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

30 of the 63 studies in Fatty Liver with a site in China are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 117 Fatty Liver studies recruiting now, 35 (30%) set no upper age limit and 63 (54%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Fatty Liver with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating the efficacy and safety of UBT251 in MASH subjects. Subjects will be randomly assigned to UBT251 2mg-dose, 4mg-dose,6mg-dose and placebo groups. The entire trial cycle includes a 6-week screening period, a 48-week double-blind treatment period, and a 4-week follow-up period.

03

Conditions studied

  • Metabolic Dysfunction-associated Steatohepatitis (MASH)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age 18-75 years (inclusive) at screening; sex unrestricted.

Subjects with centrally confirmed MASH (metabolic dysfunction-associated steatohepatitis) based on liver histopathology must meet all the following criteria:

  1. NAS (Appendix 1) ≥ 4 (with at least 1 point each for lobular inflammation and ballooning degeneration);
  2. CRN fibrosis stage (see Appendix 2) of F2 or F3 (a liver obtained ≤ 6 months before screening is acceptable if it meets the above criteria).

3.Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF) ≥ 8 % at screening (MRI-PDFF results obtained within 2 months prior to screening at the trial site are acceptable).

4.Subjects must have \<5% body weight fluctuation during the 6 weeks prior to randomization (based on self-reported data), calculated as: [(Highest weight - Lowest weight) / Highest weight] × 100%. For subjects using historical liver biopsy, documented weight change from biopsy to randomization must also be \< 5 %.

5.At least one cardiometabolic risk factor at screening:

  1. (BMI) ≥ 24.0 kg/m², or waist circumference ≥90 cm for males or ≥85 cm for females;
  2. Blood pressure ≥ 130/85 mmHg, or on antihypertensive therapy;
  3. Fasting triglycerides ≥ 1.70 mmol/L and \< 5.6 mmol/L, or on lipid-lowering therapy;
  4. Fasting HDL-C ≤ 1.0 mmol/L for males or ≤ 1.3 mmol/L for females; or on lipid-lowering therapy;
  5. Fasting glucose ≥ 6.1 mmol/L or (HbA1c) ≥ 5.7 %, or documented history of type 2 diabetes mellitus (T2DM), or Homeostatic Model Assessment of Insulin Resistance index ≥ 2.5.

6.Subjects with type 2 diabetes mellitus (T2DM) must meet glycated hemoglobin (HbA1c) ≤ 9.0 % at screening (local result obtained ≤ 2 weeks before randomization accepted), and stable glycemic control regimen for at least 3 months prior to screening: subjects must be on diet and exercise control alone, or in combination with stable-dose glucose-lowering medications, with the following requirements::

  1. Diet and exercise alone;
  2. Stable-dose use of metformin, sulfonylureas, sodium-glucose cotransporter-2 (SGLT2) inhibitors, or insulin, stable insulin dose defined as ≤35% variation in total daily insulin dose; 7. Subjects (including partners) must have no pregnancy plans from screening through 6 months post-trial and must practice during the study, with no plans to donate sperm/oocytes for 6 months after trial completion.

8. Subjects must provide prior to trial participation and voluntarily sign the written informed consent form.

9.Voluntarily comply with all trial follow-up requirements, demonstrate good protocol adherence, and be willing and able to undergo protocol-specified liver biopsies.

Exclusion criteria

Exclusion Criteria:

  1. Known to the product or any of its , or allergy to other GLP-1 receptor agonists, or history of multiple/severe drug allergies, or current allergic diseases or hypersensitivity diathesis;
  2. Previous use of any of the following drugs or treatments:

1) Use of GLP-1 receptor agonists (GLP-1R), or GLP-1R/GCGR agonists, or GLP-1R/GIPR/GCGR agonists within 3 months prior to screening; 2) Cumulative use for ≥4 weeks within 3 months prior to screening, use within 1 month prior to screening, or planned use during the trial of vitamin E (dose >400 IU/day), thiazolidinediones, polyunsaturated fatty acids, or ursodeoxycholic acid; 3) Cumulative use for ≥4 weeks within 3 months prior to screening, use within 1 month prior to screening, or planned use during the trial of drugs associated with liver injury, hepatic steatosis, or steatohepatitis: including amiodarone, methotrexate, systemic (dose >5 mg/day prednisone equivalent), estrogens (dose exceeding hormone replacement therapy or use), tetracyclines, tamoxifen, anabolic steroids, valproate, or restricted drugs, or any drug deemed likely to interfere with efficacy or safety evaluations; 4) Unstable doses of statins, fibrates, or PCSK9 inhibitors within 1 month prior to screening; 3.History or evidence of any of the following diseases:

  1. Chronic liver disease other than MASH (e.g., liver disease, primary biliary cholangitis, primary sclerosing cholangitis, chronic liver disease-related ascites, esophageal varices, hepatic encephalopathy, etc.).
  2. Diagnosis of type 1 diabetes or other specific types of diabetes, except resolved gestational diabetes;
  3. Acute pancreatitis or chronic pancreatitis within 1 year prior to screening, history of pancreatic surgery; or symptomatic gallbladder disease within 1 year prior to screening (e.g., choledocholithiasis, multiple gallstones, etc., except those who underwent cholecystectomy or stone removal);
  4. Personal or family history (first-degree relatives-parents, children, or siblings) of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2);
  5. History of severe psychiatric disorders, including but not limited to depression, suicidal tendencies or attempts, schizophrenia, bipolar disorder, etc.;
  6. Clinically significant active cardiovascular/cerebrovascular disease within 6 months prior to screening, defined as: ① Myocardial infarction (MI) or unstable angina; ② Cardiac-related surgery (including coronary artery bypass grafting, percutaneous coronary intervention); ③Congestive heart failure ( [NYHA] Class III-IV) (see Appendix 3); ④ Cerebrovascular accident (except old lacunar infarction), including but not limited to stroke/; ⑤ Other cardiovascular or cerebrovascular diseases deemed unsuitable for trial participation by the investigator;
  7. Retinal diseases requiring urgent treatment at screening (including but not limited to retinal vascular disorders, retinal inflammation, retinal detachment, retinal degeneration, etc.), as assessed by the investigator;
  8. History of severe hypoglycemic coma or frequent hypoglycemia (≥1 episode/week) within 2 months prior to enrollment (defined as fingertip or venous blood glucose \<3.9 mmol/L for T2DM subjects or \<2.8 mmol/L for non-T2DM subjects);
  9. Gastroparesis or other gastrointestinal motility disorders (e.g., pyloric obstruction, intestinal obstruction, etc.), uncontrolled gastroesophageal reflux disease, or gastrointestinal conditions deemed by the investigator to increase drug-related risks (e.g., severe active ulcers, inflammatory bowel disease, acute gastroenteritis, symptomatic chronic gastritis, functional gastrointestinal disorders, intestinal tuberculosis, etc.);
  10. Major surgery, severe trauma, or severe infection within 1 month prior to screening, deemed unsuitable for participation by the investigator;
  11. History of (except adequately treated cervical carcinoma in situ, basal or squamous cell skin cancer, localized prostate cancer post-radical therapy, ductal carcinoma in situ of the breast post-radical therapy, and papillary thyroid carcinoma post-radical therapy);
  12. Concurrent diseases deemed by the investigator to affect subject safety, efficacy evaluation, or compliance, e.g., neurological, endocrine, psychiatric, etc. ; 4.Laboratory abnormalities at screening meeting any of the following criteria:

1) Hepatic or renal impairment, based on each hospital laboratory's reference values, serum and/or AST >5× (ULN); serum total ≥1.5×ULN; estimated (eGFR) \<60 mL·min-1·1.73m-2. (calculated using CKD-EPI formula see Appendix 4) ; 2) Alkaline phosphatase (ALP) >2.0×ULN; 3) count \< 100 × 10⁹/L; 4) Serum calcitonin ≥ 50 pg/mL (i.e., 50 ng/L); 5) Serum amylase or lipase > 2.0× ULN; 6) (INR) >1.2×ULN at screening; 7) Albumin \< 3.5 g/dL (35.0 g/L). 8) Uncontrolled hypertension (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg at screening), subjects may be re-screened after 1 month of initiating or adjusting antihypertensive therapy; 9) Unstable thyroid dysfunction requiring medication adjustment at screening, or clinically significant abnormal thyroid function test results necessitating treatment initiation; 10) Subjects with clinically significant abnormalities at screening, including: a) Second- or third-degree atrioventricular block; b) Long syndrome, QTcF >470 ms for females or >450 ms for males (QTcF = QT/(RR\^0.33) ); c) Wolff-Parkinson-White syndrome; or d) Other severe arrhythmias requiring treatment; 11) Abnormal physical examination, vital signs, or laboratory results deemed clinically significant by the investigator, potentially posing major risks or interfering with efficacy, safety, or PK evaluations; 5. to liver at screening, as assessed by the investigator:(1) Hepatic hemangioma or hepatic alveolar echinococcosis;(2) Extrahepatic obstructive jaundice;(3) Significant bleeding tendency, severe thrombocytopenia, or coagulation disorders;(4) Coma or uncooperative due to other conditions;(5) Infection at the puncture site; 6.Positive for surface antigen, positive for hepatitis B core antibody (except those with positive anti-HBc but hepatitis B virus deoxyribonucleic acid [HBV-DNA] below the lower limit of the reference range), positive for virus antibody with hepatitis C virus ribonucleic acid (HCV-RNA) above the upper limit of the reference range (subjects with a history of HCV infection may be enrolled if HCV PCR has been negative for more than 3 years), positive for antibody, or positive for syphilis antibody (except cured syphilis) will be excluded; 7.Blood loss or donation > 400 mL within 3 months prior to screening, receipt of blood/component transfusions; or concurrent hemoglobinopathy, hemolytic anemia, or sickle-cell disease.

8.MRI contraindications, including but not limited to severe claustrophobia, large tattoos, inner ear implants, pacemakers or other implantable rhythm management devices, MRI-incompatible intracranial aneurysm clips, or other non-MRI-compatible metal implants (e.g., insulin pumps, hip replacements); 9.Participation in other clinical trial within 3 months prior to screening or 5 half-lives of the investigational drug (whichever is longer)(except for screening-only or non-interventional studies): 10.Excessive alcohol consumption within 12 months prior to screening, defined as >210 g/week (male) or >140 g/week (female) of ethanol (alcohol) for >3 months. Ethanol intake [g] = volume [mL] × alcohol percentage × 0.8); 11.Lactating or pregnant females; 12.Intolerance to venipuncture or history of needle/phobia; 13.Other conditions deemed unsuitable for trial participation by the investigator.

Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
156 participants (estimated)

Study arms

  • Experimental
    UBT251 Low Dose

    Dose level 1,SC, once a week for 4 weeks; Dose level 2,SC, once a week for 4 weeks; Dose level 3,SC,once a week for 4 weeks; Dose level 3,SC, once a week for 36 weeks.

    Drug: UBT251

  • Placebo comparator
    Placebo

    Placebo administered subcutaneously (SC) once a week for 48 weeks.

    Drug: Placebo

  • Experimental
    UBT251 Middle Dose

    Dose level 2,SC, once a week for 4 weeks; Dose level 3,SC, once a week for 4 weeks; Dose level 4,SC,once a week for 4 weeks; Dose level 4,SC, once a week for 36 weeks.

    Drug: UBT251

  • Experimental
    UBT251 High Dose

    Dose level 2,SC, once a week for 4 weeks; Dose level 3,SC, once a week for 4 weeks; Dose level 4,SC,once a week for 4 weeks; Dose level 5,SC, once a week for 36 weeks.

    Drug: UBT251

Interventions

  • DrugUBT251

    UBT251 administered subcutaneously (SC) once a week.

  • DrugPlacebo

    Placebo,SC,once a week for 48 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With MASH resolution With no Worsening of Fibrosis on Liver Histology

    Time frame: Baseline, Week 48

Secondary outcomes

  1. Proportion of Participants with MASH improvement with a ≥1-stage histological improvement in liver fibrosis.

    Time frame: Baseline, Week 48

  2. Proportion of Participants with MASH resolution with a ≥1-stage histological improvement in liver fibrosis.

    Time frame: Baseline, Week 48

  3. Percentage of Participants With ≥1 Point Decrease in Fibrosis Stage With No Worsening of MASH on Liver Histology

    Time frame: Baseline, Week 48

  4. Mean Absolute Change and Percent Change from Baseline in Body Weight [kg]

    Time frame: Baseline, Week 12, Week 24, Week 48

  5. Changes from baseline in waist circumference[cm]

    Time frame: Baseline, Week 12, Week 24, Week 48

  6. Changes from baseline in waist-to-hip ratio[%]

    Time frame: Baseline, Week 12, Week 24, Week 48

  7. Change from baseline in liver stiffness measurement (LSM) and controlled attenuation parameter (CAP).

    Time frame: Baseline, Week 24, Week 48

  8. Percentage change from baseline in MRI-PDFF.

    Time frame: Baseline, Week 24, Week 48

  9. Proportion of subjects achieving >30%, >50%, or >70% reduction in MRI-PDFF from baseline.

    Time frame: Baseline, Week 24, Week 48

  10. Mean Absolute Change and Percentage change From Baseline in triglyceride [mmol/L]

    Time frame: Baseline, Week 12, Week 24, Week 48

  11. Mean Absolute Change and Percentage change From Baseline in total cholesterol[mmol/L]

    Time frame: Baseline, Week 12, Week 24, Week 48

  12. Mean Absolute Change and Percentage change From Baseline in low-density lipoprotein cholesterol[mmol/L]

    Time frame: Baseline, Week 12, Week 24, Week 48

  13. Mean Absolute Change and Percentage change From Baseline in high-density lipoprotein cholesterol[mmol/L]

    Time frame: Baseline, Week 12, Week 24, Week 48

  14. Changes from baseline in fasting insulin (FINS)

    Time frame: Baseline, Week 24, Week 48

  15. Change from Baseline in homeostatic model assessment of insulin resistance (HOMA-IR)

    Time frame: Baseline, Week 24, Week 48

  16. Change from Baseline in Homeostasis Model Assessment of β-cell function (HOMA-β)

    Time frame: Baseline, Week 24, Week 48

  17. Percentage change from baseline in hepatic enzymes alanine aminotransferase (ALT) [%]

    Time frame: Baseline, Week 12, Week 24, Week 48

  18. Percentage change from baseline in hepatic enzymes aspartate aminotransferase (AST) [%]

    Time frame: Baseline, Week 12, Week 24, Week 48

  19. Percentage change from baseline in cytokeratin-18 (CK18) fragments[%]

    Time frame: Baseline, Week 12, Week 24, Week 48

  20. Percentage change from baseline in type III procollagen N-terminal propeptide (Pro-C3)[%]

    Time frame: Baseline, Week 12, Week 24, Week 48

  21. Percentage change from baseline in high-sensitivity C-reactive protein (hsCRP)[%]

    Time frame: Baseline, Week 12, Week 24, Week 48

  22. Change from baseline in scores in Fibrosis-4 Index (FIB-4)

    Time frame: Baseline, Week 12, Week 24, Week 48

  23. Change from baseline in scores in Enhanced Liver Fibrosis (ELF)

    Time frame: Baseline, Week 12, Week 24, Week 48

  24. Change from baseline in scores in NAFLD Fibrosis Score (NFS)

    Time frame: Baseline, Week 12, Week 24, Week 48

  25. Change from baseline in scores in AST-to-Platelet Ratio Index (APRI)

    Time frame: Baseline, Week 12, Week 24, Week 48

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Jun 2027, 20 months after the start.

Of 41 phase 2 interventional studies under Fatty Liver, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 36. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2025
First posted
Aug 28, 2025
StartActual
Sep 30, 2025
Primary completionEst.
Jun 4, 2027
CompletionEst.
Aug 31, 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07145151
Responsible party
Sponsor
First posted
Aug 28, 2025
Start date
Sep 30, 2025
Primary completion
Jun 4, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Haiyan Zhang
Contact
zhanghy@tul.com.cn
+86 189 9816 5570

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: UBT251

Start the discussion